Abstract: Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may augment the efficacy of cancer therapy.

Abstract: Disclosed herein is a method for enhancing the susceptibility of a subject having epidermoid carcinoma toward a tyrosine kinase inhibitor. The method includes administering to the subject an effective amount of a targeted therapy sensitizer and an effective amount of gefitinib. According to various embodiments of the present disclosure, the targeted therapy sensitizer consists of rapamycin and a substituted quinoline, such as chloroquine. Also included herein is a pharmaceutical composition that includes an effective amount of gefitinib, an effective amount of a targeted therapy sensitizer for synergistically improving or enhancing the efficacy of the gefitinib for treating epidermoid carcinoma in a subject in need thereof, and a pharmaceutically acceptable excipient.

Abstract: A cancer therapy sensitizer is disclosed. The cancer therapy sensitizer includes rapamycin and substituted quinoline. The present invention discloses a cancer therapy sensitization kit containing the two aforementioned compounds and a use of a combination of the two aforementioned compounds as a cancer therapy sensitizer as well. The application of the cancer therapy sensitizer, the kit and the use of the present invention is advantageous for improving the treatment effect of cancer therapies.

Abstract: A method for assessing a subject to receive radiation therapy in accordance with the present invention includes the steps of obtaining a body fluid sample from the subject, measuring the concentration of serum amyloid A proteins of the body fluid sample and comparing the concentration of the serum amyloid A proteins with a range of values to determine whether the subject is suitable to receive radiation therapy. Additionally, the present invention also provides a use of serum amyloid A proteins for assessing whether a subject is suitable to receive radiation therapy.

Abstract: An immune enhancement composition is disclosed. The immune enhancement composition includes rapamycin, substituted quinoline and a pharmaceutically acceptable carrier, diluent, excipient or a combination thereof. An immune enhancement kit containing the two aforementioned compounds and a use of a combination containing the two aforementioned compounds as an immune enhancement composition are also disclosed. The application of the composition, kit and use is advantageous for promoting the activity of the immune system.

Abstract: A cancer therapy sensitizer is disclosed. The cancer therapy sensitizer includes rapamycin and substituted quinoline. The present invention discloses a cancer therapy sensitization kit containing the two aforementioned compounds and a use of a combination of the two aforementioned compounds as a cancer therapy sensitizer as well. The application of the cancer therapy sensitizer, the kit and the use of the present invention is advantageous for improving the treatment effect of cancer therapies.

Abstract: A target therapy sensitizer including rapamycin and substituted quinoline is disclosed. In addition, a pharmaceutical composition containing the sensitizer, a target therapy sensitization kit containing the two aforementioned compounds, and a use of a combination of the two aforementioned compounds as a target therapy sensitizer are also disclosed. The application of the target therapy sensitizer, pharmaceutical composition, kit and use is advantageous for improving the treatment effect of target therapies.